Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
The Prospect of Targeting T Cell Immunoglobulin and Mucin-Domain Containing-3 in Renal Cell Carcinoma Immunotherapy Publisher Pubmed



Mohsenzadegan M1 ; Nowroozi MR2 ; Fotovvat A2 ; Bavandpour Baghshahi P3 ; Bokaie S4 ; Inanloo SH2 ; Sharifi L2
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Medical Laboratory Science, Faculty of Allied Medical Sciences, Iran University of Medical Sciences, Tehran, Iran
  2. 2. Uro-Oncology Research Center, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Department of Immunology, School of Medicine, Babol University of Medical Sciences, Babol, Iran
  4. 4. Department of Epidemiology, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran

Source: Scandinavian Journal of Immunology Published:2022


Abstract

Despite the advances in the diagnosis and treatment of renal cell carcinoma (RCC), it remains one of the most deadly urological cancers. At present, using immune checkpoint inhibition and their combination with antiangiogenic therapy is the standard of care in patients with advanced RCC. Unfortunately, a considerable part of tumour-bearing hosts does not benefit from this type of treatment. However, our knowledge about the detailed role of mucin-domain containing-3 (TIM-3) in the RCC cells is little, and further studies are required in this field, but its significant expression in the RCC microenvironment makes this receptor a promising target for designing new monoclonal antibodies alone or in combination with other checkpoint inhibitors for RCC immunotherapy. © 2022 The Scandinavian Foundation for Immunology.
Related Docs
View other Related Docs
1. The Potential of T Cell Immunoglobulin and Mucin-Domain Containing-3 (Tim-3) in Designing Novel Immunotherapy for Bladder Cancer, Endocrine# Metabolic and Immune Disorders - Drug Targets (2021)
2. Immunotherapeutic Targets in Non-Small Cell Lung Cancer, Immunology (2023)
3. Clinical Potential of Pd-1/Pd-L1 Blockade Therapy for Renal Cell Carcinoma (Rcc): A Rapidly Evolving Strategy, Cancer Cell International (2022)
4. Targeted Knockdown of Tim3 by Short Hairpin Rnas Improves the Function of Anti-Mesothelin Car T Cells, Molecular Immunology (2021)
5. Tumor Immunology, Clinical Immunology (2022)
6. Exhaustion of T Lymphocytes in the Tumor Microenvironment: Significance and Effective Mechanisms, Cellular Immunology (2017)
7. Immune Checkpoint Blockade in Melanoma: Advantages, Shortcomings and Emerging Roles of the Nanoparticles, International Immunopharmacology (2022)
8. Immune Checkpoints and Ncrnas: Pioneering Immunotherapy Approaches for Hematological Malignancies, Cancer Cell International (2024)
Experts (# of related papers)
View all Related Experts
Nima Rezaei (10)
Hamid Reza Mirzaei (2)
Other Related Docs
9. A Comprehensive Review About the Utilization of Immune Checkpoint Inhibitors and Combination Therapy in Hepatocellular Carcinoma: An Updated Review, Cancer Cell International (2022)
10. Sequential Monitoring of Tim-3 Mrna Expression in Blood and Urine Samples of Renal Transplant Recipients, Transplant Immunology (2019)
11. Upregulation of Galectin-9 and Pd-L1 Immune Checkpoints Molecules in Patients With Chronic Lymphocytic Leukemia, Asian Pacific Journal of Cancer Prevention (2017)
12. Immune Checkpoint Inhibitor (Ici) Therapy in Central Nervous System Cancers: State-Of-The-Art and Future Outlook, International Immunopharmacology (2025)
13. Car-Nk Cells for Haematological Cancers, Best Practice and Research: Clinical Haematology (2025)
14. Resistance Mechanisms to Programmed Cell Death Protein 1 and Programmed Death Ligand 1 Inhibitors, Expert Opinion on Biological Therapy (2021)
15. Immunotherapy of Cancers Comes of Age, Expert Review of Clinical Immunology (2017)
16. Tim-3 Genetic Variants and Risk of Behcet Disease in the Iranian Population, Anais Brasileiros de Dermatologia (2019)
17. Resistance to Immunotherapy in Human Malignancies: Mechanisms, Research Progresses, Challenges, and Opportunities, Journal of Cellular Physiology (2022)
18. Cancer Immunology, Encyclopedia of Infection and Immunity (2022)
19. The Therapeutic Potential of Regulatory T Cells: Challenges and Opportunities, Frontiers in Immunology (2021)
20. Study of T-Cell Immunoglobulin and Mucin Domain-3 Expression Profile in Peripheral Blood and Bone Marrow of Human Acute Lymphoblastic Leukemia Patients, Journal of Research in Medical Sciences (2020)
21. Evaluation of the Immune Checkpoint Factors in Idiopathic Membranous Nephropathy, Molecular and Cellular Probes (2023)
22. Recent Advances in Immune Checkpoint Therapy in Non-Small Cell Lung Cancer and Opportunities for Nanoparticle-Based Therapy, European Journal of Pharmacology (2021)
23. Cancer Immunotherapy Confers a Global Benefit, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)
24. Crispri-Mediated Knock-Down of Prdm1/Blimp1 Programs Central Memory Differentiation in Ex Vivo-Expanded Human T Cells, BioImpacts (2022)
25. High Expression of Tim-3 and Kim-1 in Blood and Urine of Renal Allograft Rejection Patients, Transplant Immunology (2017)
26. Contribution of Natural Killer Cells in Innate Immunity Against Colorectal Cancer, Frontiers in Oncology (2023)
27. Natural Killer Cell-Based Therapies in Neuroblastoma, Cellular Immunology (2025)
28. Advances in Therapeutic Targeting of Immune Checkpoints Receptors Within the Cd96-Tigit Axis: Clinical Implications and Future Perspectives, Expert Review of Clinical Immunology (2022)
29. Pd-1/Pd-L1 Pathway: Basic Biology and Role in Cancer Immunotherapy, Journal of Cellular Physiology (2019)
30. Immunotherapeutic Approaches in Cancer, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2018)
31. The Current Landscape of Car T-Cell Therapy for Solid Tumors: Mechanisms, Research Progress, Challenges, and Counterstrategies, Frontiers in Immunology (2023)
32. Immunotherapeutic Approaches in Cancer, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2019)
33. Renal Cell Carcinoma: An Overview of the Epidemiology, Diagnosis, and Treatment, Giornale Italiano di Nefrologia (2022)
34. Combining Anti-Checkpoint Immunotherapies and Cancer Vaccines As a Novel Strategy in Oncological Therapy: A Review, Human Immunology (2025)
35. Therapeutic and Immunomodulatory Potentials of Mesenchymal Stromal/Stem Cells and Immune Checkpoints Related Molecules, Biomarker Research (2024)
36. Biomarkers for Immune Checkpoint Inhibitors, Cancer Immunology: Bench to Bedside Immunotherapy of Cancers# Second Edition (2020)
37. Targeting Regulatory T Cells by Curcumin: A Potential for Cancer Immunotherapy, Pharmacological Research (2019)